Sarah De Keulenaer
Ghent University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sarah De Keulenaer.
Nucleic Acids Research | 2015
Jeroen Crappé; Elvis Ndah; Alexander Koch; Sandra Steyaert; Daria Gawron; Sarah De Keulenaer; Ellen De Meester; Tim De Meyer; Wim Van Criekinge; Petra Van Damme; Gerben Menschaert
An increasing amount of studies integrate mRNA sequencing data into MS-based proteomics to complement the translation product search space. However, several factors, including extensive regulation of mRNA translation and the need for three- or six-frame-translation, impede the use of mRNA-seq data for the construction of a protein sequence search database. With that in mind, we developed the PROTEOFORMER tool that automatically processes data of the recently developed ribosome profiling method (sequencing of ribosome-protected mRNA fragments), resulting in genome-wide visualization of ribosome occupancy. Our tool also includes a translation initiation site calling algorithm allowing the delineation of the open reading frames (ORFs) of all translation products. A complete protein synthesis-based sequence database can thus be compiled for mass spectrometry-based identification. This approach increases the overall protein identification rates with 3% and 11% (improved and new identifications) for human and mouse, respectively, and enables proteome-wide detection of 5′-extended proteoforms, upstream ORF translation and near-cognate translation start sites. The PROTEOFORMER tool is available as a stand-alone pipeline and has been implemented in the galaxy framework for ease of use.
BMC Medical Genomics | 2012
Sarah De Keulenaer; Jan Hellemans; Steve Lefever; Jean-Pierre Renard; Joachim De Schrijver; Hendrik Van de Voorde; Mohammad Amin Tabatabaiefar; Filip Van Nieuwerburgh; Daisy Flamez; Filip Pattyn; Bieke Scharlaken; Dieter Deforce; Sofie Bekaert; Wim Van Criekinge; Jo Vandesompele; Guy Van Camp; Paul Coucke
BackgroundHereditary hearing loss (HL) can originate from mutations in one of many genes involved in the complex process of hearing. Identification of the genetic defects in patients is currently labor intensive and expensive. While screening with Sanger sequencing for GJB2 mutations is common, this is not the case for the other known deafness genes (> 60). Next generation sequencing technology (NGS) has the potential to be much more cost efficient. Published methods mainly use hybridization based target enrichment procedures that are time saving and efficient, but lead to loss in sensitivity. In this study we used a semi-automated PCR amplification and NGS in order to combine high sensitivity, speed and cost efficiency.ResultsIn this proof of concept study, we screened 15 autosomal recessive deafness genes in 5 patients with congenital genetic deafness. 646 specific primer pairs for all exons and most of the UTR of the 15 selected genes were designed using primerXL. Using patient specific identifiers, all amplicons were pooled and analyzed using the Roche 454 NGS technology. Three of these patients are members of families in which a region of interest has previously been characterized by linkage studies. In these, we were able to identify two new mutations in CDH23 and OTOF. For another patient, the etiology of deafness was unclear, and no causal mutation was found. In a fifth patient, included as a positive control, we could confirm a known mutation in TMC1.ConclusionsWe have developed an assay that holds great promise as a tool for screening patients with familial autosomal recessive nonsyndromal hearing loss (ARNSHL). For the first time, an efficient, reliable and cost effective genetic test, based on PCR enrichment, for newborns with undiagnosed deafness is available.
PLOS ONE | 2013
Tim De Meyer; Evi Mampaey; Michaël Vlemmix; Simon Denil; Geert Trooskens; Jean Pierre Renard; Sarah De Keulenaer; Pierre Dehan; Gerben Menschaert; Wim Van Criekinge
DNA-methylation is an important epigenetic feature in health and disease. Methylated sequence capturing by Methyl Binding Domain (MBD) based enrichment followed by second-generation sequencing provides the best combination of sensitivity and cost-efficiency for genome-wide DNA-methylation profiling. However, existing implementations are numerous, and quality control and optimization require expensive external validation. Therefore, this study has two aims: 1) to identify a best performing kit for MBD-based enrichment using independent validation data, and 2) to evaluate whether quality evaluation can also be performed solely based on the characteristics of the generated sequences. Five commercially available kits for MBD enrichment were combined with Illumina GAIIx sequencing for three cell lines (HCT15, DU145, PC3). Reduced representation bisulfite sequencing data (all three cell lines) and publicly available Illumina Infinium BeadChip data (DU145 and PC3) were used for benchmarking. Consistent large-scale differences in yield, sensitivity and specificity between the different kits could be identified, with Diagenodes MethylCap kit as overall best performing kit under the tested conditions. This kit could also be identified with the Fragment CpG-plot, which summarizes the CpG content of the captured fragments, implying that the latter can be used as a tool to monitor data quality. In conclusion, there are major quality differences between kits for MBD-based capturing of methylated DNA, with the MethylCap kit performing best under the used settings. The Fragment CpG-plot is able to monitor data quality based on inherent sequence data characteristics, and is therefore a cost-efficient tool for experimental optimization, but also to monitor quality throughout routine applications.
PLOS ONE | 2011
Kim De Leeneer; Joachim De Schrijver; Lieven Clement; Machteld Baetens; Steve Lefever; Sarah De Keulenaer; Wim Van Criekinge; Dieter Deforce; Filip Van Nieuwerburgh; Sofie Bekaert; Filip Pattyn; Bram De Wilde; Paul Coucke; Jo Vandesompele; Kathleen Claes; Jan Hellemans
Despite improvements in terms of sequence quality and price per basepair, Sanger sequencing remains restricted to screening of individual disease genes. The development of massively parallel sequencing (MPS) technologies heralded an era in which molecular diagnostics for multigenic disorders becomes reality. Here, we outline different PCR amplification based strategies for the screening of a multitude of genes in a patient cohort. We performed a thorough evaluation in terms of set-up, coverage and sequencing variants on the data of 10 GS-FLX experiments (over 200 patients). Crucially, we determined the actual coverage that is required for reliable diagnostic results using MPS, and provide a tool to calculate the number of patients that can be screened in a single run. Finally, we provide an overview of factors contributing to false negative or false positive mutation calls and suggest ways to maximize sensitivity and specificity, both important in a routine setting. By describing practical strategies for screening of multigenic disorders in a multitude of samples and providing answers to questions about minimum required coverage, the number of patients that can be screened in a single run and the factors that may affect sensitivity and specificity we hope to facilitate the implementation of MPS technology in molecular diagnostics.
Proteomics | 2014
Alexander Koch; Daria Gawron; Sandra Steyaert; Elvis Ndah; Jeroen Crappé; Sarah De Keulenaer; Ellen De Meester; Ming Ma; Ben Shen; Kris Gevaert; Wim Van Criekinge; Petra Van Damme; Gerben Menschaert
Next‐generation transcriptome sequencing is increasingly integrated with MS to enhance MS‐based protein and peptide identification. Recently, a breakthrough in transcriptome analysis was achieved with the development of ribosome profiling (ribo‐seq). This technology is based on the deep sequencing of ribosome‐protected mRNA fragments, thereby enabling the direct observation of in vivo protein synthesis at the transcript level. In order to explore the impact of a ribo‐seq‐derived protein sequence search space on MS/MS spectrum identification, we performed a comprehensive proteome study on a human cancer cell line, using both shotgun and N‐terminal proteomics, next to ribosome profiling, which was used to delineate (alternative) translational reading frames. By including protein‐level evidence of sample‐specific genetic variation and alternative translation, this strategy improved the identification score of 69 proteins and identified 22 new proteins in the shotgun experiment. Furthermore, we discovered 18 new alternative translation start sites in the N‐terminal proteomics data and observed a correlation between the quantitative measures of ribo‐seq and shotgun proteomics with a Pearson correlation coefficient ranging from 0.483 to 0.664. Overall, this study demonstrated the benefits of ribosome profiling for MS‐based protein and peptide identification and we believe this approach could develop into a common practice for next‐generation proteomics.
Scientific Reports | 2015
Bart Broeckx; Frank Coopman; Geert Verhoeven; Valérie Bavegems; Sarah De Keulenaer; Ellen De Meester; Filip Van Niewerburgh; Dieter Deforce
Whole exome sequencing is a technique that aims to selectively sequence all exons of protein-coding genes. A canine whole exome sequencing enrichment kit was designed based on the latest canine reference genome (build 3.1.72). Its performance was tested by sequencing 2 exome captures, each consisting of 4 pre-capture pooled, barcoded Illumina libraries on an Illumina HiSeq 2500. At an average sequencing depth of 102x, 83 to 86% of the target regions were completely sequenced with a minimum coverage of five and 90% of the reads mapped on the target regions. Additionally, it is shown that the reproducibility within and between captures is high and that pooling four samples per capture is a valid option. Overall, we have demonstrated the strong performance of this WES enrichment kit and are confident it will be a valuable tool in future disease association studies.
Scientific Reports | 2015
Bart Broeckx; Christophe Hitte; Frank Coopman; Geert Verhoeven; Sarah De Keulenaer; Ellen De Meester; Thomas Derrien; Jessica Alföldi; Kerstin Lindblad-Toh; Tim Bosmans; Ingrid Gielen; Henri van Bree; Bernadette Van Ryssen; Jimmy Saunders; Filip Van Nieuwerburgh; Dieter Deforce
By limiting sequencing to those sequences transcribed as mRNA, whole exome sequencing is a cost-efficient technique often used in disease-association studies. We developed two target enrichment designs based on the recently released annotation of the canine genome: the exome-plus design and the exome-CDS design. The exome-plus design combines the exons of the CanFam 3.1 Ensembl annotation, more recently discovered protein-coding exons and a variety of non-coding RNA regions (microRNAs, long non-coding RNAs and antisense transcripts), leading to a total size of ≈152 Mb. The exome-CDS was designed as a subset of the exome-plus by omitting all 3’ and 5’ untranslated regions. This reduced the size of the exome-CDS to ≈71 Mb. To test the capturing performance, four exome-plus captures were sequenced on a NextSeq 500 with each capture containing four pre-capture pooled, barcoded samples. At an average sequencing depth of 68.3x, 80% of the regions and well over 90% of the targeted base pairs were completely covered at least 5 times with high reproducibility. Based on the performance of the exome-plus, we estimated the performance of the exome-CDS. Overall, these designs provide flexible solutions for a variety of research questions and are likely to be reliable tools in disease studies.
Scientific Reports | 2016
Sandra Steyaert; Jolien Diddens; Jeroen Galle; Ellen De Meester; Sarah De Keulenaer; Antje Bakker; Nina Sohnius-Wilhelmi; Carolina Frankl-Vilches; Anne-Marie Van Der Linden; Wim Van Criekinge; Wim Vanden Berghe; Tim De Meyer
Learning and memory formation are known to require dynamic CpG (de)methylation and gene expression changes. Here, we aimed at establishing a genome-wide DNA methylation map of the zebra finch genome, a model organism in neuroscience, as well as identifying putatively epigenetically regulated genes. RNA- and MethylCap-seq experiments were performed on two zebra finch cell lines in presence or absence of 5-aza-2′-deoxycytidine induced demethylation. First, the MethylCap-seq methodology was validated in zebra finch by comparison with RRBS-generated data. To assess the influence of (variable) methylation on gene expression, RNA-seq experiments were performed as well. Comparison of RNA-seq and MethylCap-seq results showed that at least 357 of the 3,457 AZA-upregulated genes are putatively regulated by methylation in the promoter region, for which a pathway analysis showed remarkable enrichment for neurological networks. A subset of genes was validated using Exon Arrays, quantitative RT-PCR and CpG pyrosequencing on bisulfite-treated samples. To our knowledge, this study provides the first genome-wide DNA methylation map of the zebra finch genome as well as a comprehensive set of genes of which transcription is under putative methylation control.
International Journal of Molecular Sciences | 2018
Lotte Vermeulen; Juan Fraire; Laurens Raes; Ellen De Meester; Sarah De Keulenaer; Filip Van Nieuwerburgh; Stefaan C. De Smedt; Katrien Remaut; Kevin Braeckmans
Plasmonic nanoparticles for drug delivery have attracted increasing interest over the last few years. Their localized surface plasmon resonance causes photothermal effects on laser irradiation, which allows for delivering drugs in a spatio-temporally controlled manner. Here, we explore the use of gold nanoparticles (AuNP) as carriers for pDNA in combination with pulsed laser irradiation to induce endosomal escape, which is currently considered to be one of the major bottlenecks in macromolecular drug delivery on the intracellular level. In particular, we evaluate nanocomplexes composed of JetPEI (polyethylenimine)pDNA and 10 nm AuNP, which do not exhibit endosomal escape by themselves. After incubating HeLa cells with these complexes, we evaluated endosomal escape and transfection efficiency using low- and high-energy laser pulses. At low laser energy heat is produced by the nanocomplexes, while, at higher laser energy, explosive vapour nanobubbles (VNB) are formed. We investigated the ability of heat transfer and VNB formation to induce endosomal escape and we examine the integrity of pDNA cargo after inducing both photothermal effects. We conclude that JetPEI/pDNA/AuNP complexes are unable to induce meaningful transfection efficiencies because laser treatment causes either dysfunctionality of the cargo when VNB are formed or forms too small pores in the endosomal membrane to allow pDNA to escape in case of heating. We conclude that laser-induced VNB is the most suitable to induce effective pDNA endosomal escape, but a different nanocomplex structure will be required to keep the pDNA intact.
Scientific Reports | 2016
Sandra Steyaert; Jolien Diddens; Jeroen Galle; Ellen De Meester; Sarah De Keulenaer; Antje Bakker; Nina Sohnius-Wilhelmi; Carolina Frankl-Vilches; Annemie Van der Linden; Wim Van Criekinge; Wim Vanden Berghe; Tim Meyer
Scientific Reports 6: Article number: 20957; 10.1038/srep20957 published online: February112016; updated: March172016 The original version of this Article contained an error in the title of the paper, where the word “epigenetically” was incorrectly given as “eigenetically”. This has now been corrected in the PDF and HTML versions of the Article.